NCT06659640View on ClinicalTrials.gov

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

January 5, 2028

Study Completion Date

June 21, 2028

Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
DRUG

ALN-6400

ALN-6400 will be administered subcutaneously (SC)

DRUG

Placebo

Placebo will be administered subcutaneously (SC)

Trial Locations (2)

90630

RECRUITING

Clinical Trial Site, Cypress

Unknown

RECRUITING

Clinical Trial Site, Montreal

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY